InflaRx Toekomstige groei
Future criteriumcontroles 2/6
De verwachting is dat InflaRx de winst en omzet met respectievelijk 35.3% en 65.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 41.1% per jaar.
Belangrijke informatie
35.3%
Groei van de winst
41.1%
Groei van de winst per aandeel
Biotechs winstgroei | 28.3% |
Inkomstengroei | 65.8% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 15 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely
Jun 25We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Dec 23InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 17We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Mar 28Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?
Nov 30InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients
Sep 29InflaRx reports Q2 results
Aug 05InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients
Jul 26Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Jul 16InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder
Jul 06InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy
Jun 29Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
Apr 01Our First Look At InflaRx
Dec 29Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)
Dec 15InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 27InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
Aug 25InflaRx initiates mid-stage vilobelimab skin cancer trial
Jun 08We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth
May 01Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?
Mar 02We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Jan 08InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder
Jan 05InflaRx reports Q3 results
Oct 29Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 1 | -60 | -20 | -28 | 3 |
12/31/2025 | 1 | -73 | -93 | -60 | 3 |
12/31/2024 | 0 | -57 | N/A | -51 | 3 |
9/30/2024 | 0 | -57 | -48 | -48 | N/A |
6/30/2024 | 0 | -47 | -43 | -43 | N/A |
3/31/2024 | 0 | -41 | -42 | -42 | N/A |
12/31/2023 | 0 | -43 | -38 | -38 | N/A |
9/30/2023 | 0 | -35 | -32 | -32 | N/A |
6/30/2023 | N/A | -35 | -30 | -30 | N/A |
3/31/2023 | N/A | -27 | -32 | -31 | N/A |
12/31/2022 | N/A | -29 | -34 | -34 | N/A |
9/30/2022 | N/A | -34 | -40 | -40 | N/A |
6/30/2022 | N/A | -38 | -47 | -47 | N/A |
3/31/2022 | N/A | -54 | -42 | -42 | N/A |
12/31/2021 | N/A | -46 | -40 | -40 | N/A |
9/30/2021 | N/A | -42 | -38 | -38 | N/A |
6/30/2021 | N/A | -37 | -37 | -37 | N/A |
3/31/2021 | N/A | -32 | -37 | -36 | N/A |
12/31/2020 | N/A | -34 | -37 | -37 | N/A |
9/30/2020 | N/A | -39 | -43 | -43 | N/A |
6/30/2020 | N/A | -46 | -43 | -43 | N/A |
3/31/2020 | N/A | -52 | -46 | -45 | N/A |
12/31/2019 | N/A | -53 | -44 | -43 | N/A |
9/30/2019 | N/A | -50 | -34 | -33 | N/A |
6/30/2019 | N/A | -42 | -30 | -29 | N/A |
3/31/2019 | N/A | -29 | -25 | -24 | N/A |
12/31/2018 | N/A | -30 | -22 | -22 | N/A |
9/30/2018 | N/A | -31 | -20 | -19 | N/A |
6/30/2018 | N/A | -29 | N/A | -18 | N/A |
3/31/2018 | N/A | -31 | N/A | -15 | N/A |
12/31/2017 | N/A | -24 | N/A | -12 | N/A |
9/30/2017 | N/A | -17 | N/A | -10 | N/A |
6/30/2017 | N/A | -15 | N/A | -8 | N/A |
3/31/2017 | N/A | -12 | N/A | -7 | N/A |
12/31/2016 | N/A | -9 | N/A | -5 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat IFRX de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat IFRX de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat IFRX de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van IFRX ( 65.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van IFRX ( 65.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van IFRX naar verwachting over 3 jaar hoog zal zijn